clinical trial · NCT05775848
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
ML Bio Solutions, Inc.·phase3·active not recruiting·n = 81
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)BBP-418 (ribitol)Placebo
brief summary
This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients based upon the established epidemiology of the disease.
started
May 31, 2023
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
Sep 29, 2025
official title
A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol